Security
Adial Pharmaceuticals Inc Warrant · ADILW
ADILWNASDAQWarrantHistorical · closed Jul 27, 2023CIK 1513525Updated Nov 11, 2026
Name history
ADIAL PHARMACEUTICALS, INC. · through Oct 30, 2026Adial Pharmaceuticals, L.L.C. · through Sep 28, 2017ADial Pharmaceuticals, L.L.C. · through Sep 28, 2017
ADILW price & chart
Historical security
This listing closed Jul 27, 2023. Live provider charts are shown only for current listings.
About the company
We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (“AUD”). AD04 was recently investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment of AUD in subjects with certain target genotypes, which were identified using our companion diagnostic genetic test. Based on our analysis of the subgroup data from the ONWARD trial, we are now focused on completing the clinical development program for AD04 in the specified genetic subgroups to meet regulatory requirements primarily in the U.S. and secondarily in Europe/U.K.
In the news
No coverage from other publishers is available.
Recent filings
3 filing
3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders · Regulation FD Disclosure
Items 5.02, 5.03, 5.07, 7.01, 9.01
EFFECT filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 5,659,847Source | 6,712,719Source | 29,089,000Source | 6,801,703Source | 4,948,703Source | 5,227,321Source | 3,451,122Source | — | 6,673,367Source | 5,043,942Source | 4,736,605Source | 5,732,804Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 50,424Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | — | 248,971Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,925Source | 3,489Source | 3,000Source | 3,066Source | 3,631Source | 2,643Source | 3,207Source | — | 2,784Source | 3,348Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,606,289Source | 5,204,346Source | — | 5,914,980Source | 3,288,048Source | — | 2,365,780Source | — | 5,881,217Source | 3,750,525Source | 2,827,082Source | 4,001,794Source |
| Assets, CurrentUSD | 5,013,832Source | 5,618,583Source | 28,845,000Source | 6,078,627Source | 3,823,402Source | 4,802,948Source | 2,629,175Source | — | 6,180,883Source | 4,058,764Source | 3,198,679Source | 4,779,935Source |
| Prepaid Expense and Other Assets, CurrentUSD | 407,543Source | 409,807Source | 133,000Source | 163,647Source | 188,600Source | 218,848Source | 263,395Source | — | 299,666Source | 308,239Source | 371,597Source | 349,441Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | — | — | — | 193,997Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,154,756Source | 829,046Source | 28,933,000Source | 1,211,027Source | 671,882Source | 1,510,071Source | 1,324,460Source | — | 1,396,909Source | 975,858Source | 653,076Source | 2,456,310Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 23,836Source | 6,404Source | 3,000Source | 21,535Source | 4,292Source | 1,509Source | 6,650Source | — | 1,111Source | 6,473Source | 1,663Source | 26,687Source |
| Additional Paid in CapitalUSD | 92,457,586Source | 85,801,802Source | 105,604,000Source | 91,751,821Source | 82,005,259Source | 95,710,627Source | 86,344,136Source | — | 95,247,841Source | 86,056,934Source | 72,879,738Source | 66,924,338Source |
| Retained Earnings (Accumulated Deficit)USD | -87,976,331Source | -79,924,533Source | -143,984,000Source | -86,182,680Source | -77,732,730Source | -91,994,886Source | -84,224,124Source | — | -89,972,494Source | -81,995,323Source | -68,797,872Source | -63,674,531Source |
| Stockholders' Equity Attributable to ParentUSD | 4,505,091Source | 5,883,673Source | -38,377,000Source | 5,590,000Source | 4,276,821Source | 3,717,250Source | 2,126,662Source | 6,121,650Source | 5,276,458Source | 4,068,084Source | 4,083,529Source | 3,276,494Source |
| Liabilities and EquityUSD | 5,659,847Source | 6,712,719Source | 29,089,000Source | 6,801,703Source | 4,948,703Source | 5,227,321Source | 3,451,122Source | — | 6,673,367Source | 5,043,942Source | 4,736,605Source | 5,732,804Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 1,154,756Source | 829,046Source | 5,121,000Source | 1,211,027Source | 671,882Source | 1,510,071Source | 1,324,460Source | — | 1,396,909Source | 975,858Source | 653,076Source | 1,790,866Source |
| Accounts Payable, CurrentUSD | 556,284Source | 318,118Source | 2,624,000Source | 671,118Source | 316,726Source | 573,567Source | 532,430Source | — | 655,207Source | 250,130Source | 103,325Source | 393,834Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 150,547Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 22,897Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 598,472Source | 500,928Source | 2,497,000Source | 539,909Source | 335,156Source | 936,504Source | 758,695Source | — | 741,702Source | 677,456Source | 477,747Source | 1,154,817Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 117,476Source |
| Deferred Compensation Equity | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | — | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 147,900Source | 236,731Source | 676,200Source | 796,831Source | 1,746,378Source | 3,374,493Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -81,640Source | 282,300Source | — | — | -183,473Source | 108,346Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | -502Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,612,401Source | -1,585,393Source | -6,492,603Source | -6,922,306Source | -6,806,809Source | -11,185,985Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 150,000Source | 150,000Source | — | 1,500,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 1,661Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 315,284Source | 50,648Source | 8,473,295Source | 7,845,749Source | 4,132,097Source | 9,125,606Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 749,943Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 4,606,289Source | 5,204,346Source | 28,712,000Source | 5,915,000Source | 4,584,100Source | 2,365,780Source | 5,881,217Source | 3,750,525Source | 2,827,082Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 147,334Source | 188,261Source | 137,000Source | 124,000Source | 147,900Source | 236,731Source | 676,200Source | 796,831Source | 1,746,378Source | 3,374,493Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 141Source | 141Source | 565Source | 565Source | — | 564Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | — | — | — | 522,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | — | 2,624,798Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,243,009Source | 1,179,841Source | 5,400,000Source | 1,150,000Source | 1,568,951Source | 1,520,402Source | 5,179,791Source | 5,055,231Source | 5,620,870Source | 9,140,129Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | — | 248,971Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -2,191,803Source | — | — | — | -2,228,801Source | — | -13,197,451Source | -7,001,890Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -7,001,890Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | 1,878,549Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -76,920Source | -31,023Source | -181,000Source | -99,000Source | -67,970Source | -163,090Source | -492,130Source | -552,183Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | -502Source |
| Investment Income, InterestUSD | — | — | 47,860Source | 50,694Source | 58,000Source | 24,000Source | 47,059Source | 35,346Source | 149,567Source | 178,659Source | 69,779Source | 63,209Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,793,651Source | -2,191,803Source | -51,989,000Source | -1,958,000Source | -2,022,392Source | -2,228,801Source | -7,977,171Source | -13,197,451Source | -5,123,341Source | -12,731,416Source |
| Nonoperating Income (Expense)USD | — | — | -29,573Source | 19,671Source | 36,000Source | -76,000Source | -20,911Source | 38,492Source | -177,709Source | -4,912,994Source | -113,943Source | 585,209Source |
| Operating ExpensesUSD | — | — | 1,764,078Source | 2,211,474Source | 52,025,000Source | 1,882,000Source | 2,001,481Source | 2,267,293Source | 7,799,462Source | 8,284,457Source | 6,887,947Source | 13,317,127Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 72,828Source |
| Other Nonoperating Income (Expense)USD | — | — | -513Source | — | — | -1,000Source | — | 166,236Source | 164,854Source | -75,043Source | — | — |
| Payments for Repurchase of WarrantsUSD | — | — | — | — | — | — | — | — | — | — | 1,150,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 315,284Source | 50,648Source | 3,658,552Source | 4,021,485Source | — | 9,123,741Source |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | — | — | — | — | — | — | — | -193,884Source | 522,000Source |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -1,764,078Source | -2,211,474Source | -52,025,000Source | -1,882,000Source | -2,001,481Source | -2,267,293Source | -7,799,462Source | -8,284,457Source | -6,887,947Source | -13,317,127Source |
| Other Nonoperating Income (Expense)USD | — | — | -513Source | — | — | -1,000Source | — | 166,236Source | 164,854Source | -75,043Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -2,191,803Source | — | — | — | — | -7,977,171Source | -13,197,451Source | -7,001,890Source | -12,731,918Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | -502Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,793,651Source | -2,191,803Source | -51,989,000Source | -1,958,000Source | -2,022,392Source | -2,228,801Source | -7,977,171Source | -13,197,451Source | -5,123,341Source | -12,731,416Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.08Source | -0.38Source | -11.25Source | -4.61Source | -1.48Source | -8.52Source | -11.93Source | -2.72Source | -3.6Source | -0.51Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.08Source | -0.38Source | -11.25Source | -4.61Source | -1.48Source | -8.52Source | -11.93Source | -2.72Source | -3.6Source | -0.51Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 22,171,309Source | 5,835,682Source | 4,621,735Source | 424,908Source | 1,370,109Source | 261,590Source | 668,630Source | — | — | 25,037,637Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 22,171,309Source | 5,835,682Source | 4,621,735Source | 424,908Source | 1,370,109Source | 261,590Source | 668,630Source | 4,851,487Source | 1,424,661Source | 25,037,637Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 141Source | 141Source | 565Source | 565Source | — | 564Source |
| Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 550,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | — | — | — | 522,000Source |
| General and Administrative ExpenseUSD | — | — | 1,243,009Source | 1,179,841Source | 5,400,000Source | 1,150,000Source | 1,568,951Source | 1,520,402Source | 5,179,791Source | 5,055,231Source | 5,620,870Source | 9,140,129Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -2,191,803Source | — | — | — | -2,228,801Source | — | -13,197,451Source | -7,001,890Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -7,977,171Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -7,001,890Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | -0.38Source | — | — | — | — | — | -2.72Source | -4.91Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -0.38Source | — | — | — | — | — | -2.72Source | -4.91Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | 1,878,549Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -76,920Source | -31,023Source | -181,000Source | -99,000Source | -67,970Source | -163,090Source | -492,130Source | -552,183Source | — | — |
| Investment Income, InterestUSD | — | — | 47,860Source | 50,694Source | 58,000Source | 24,000Source | 47,059Source | 35,346Source | 149,567Source | 178,659Source | 69,779Source | 63,209Source |
| Nonoperating Income (Expense)USD | — | — | -29,573Source | 19,671Source | 36,000Source | -76,000Source | -20,911Source | 38,492Source | -177,709Source | -4,912,994Source | -113,943Source | 585,209Source |
| Operating ExpensesUSD | — | — | 1,764,078Source | 2,211,474Source | 52,025,000Source | 1,882,000Source | 2,001,481Source | 2,267,293Source | 7,799,462Source | 8,284,457Source | 6,887,947Source | 13,317,127Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 72,828Source |
| Other Cost and Expense, OperatingUSD | — | — | — | — | — | — | — | — | — | — | 1,500,000Source | — |
| Other ExpensesUSD | — | — | — | — | — | — | — | 0Source | — | 51,901Source | 57,750Source | 398,600Source |
| Other General ExpenseUSD | — | — | — | — | — | — | — | — | 36,048Source | — | — | — |
| Other IncomeUSD | — | — | — | — | — | — | — | 150,000Source | 150,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 521,069Source | 1,031,633Source | 440,000Source | 732,000Source | 432,530Source | 746,891Source | 2,619,671Source | 3,229,226Source | 1,267,077Source | 4,176,998Source |
Offerings
Registration 333-298636
Registration 333-287826
Filing attachments
ea030997701ex99-1.htm · 8-K · 2026-10-28
Exhibit 99.1 Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis Stockholders approved the conversion of the preferred stock issued in the June 2026 acquisition of Azora Therapeutics Azora’s common stock to begin trading on Nasdaq under the ticker symbol “AZR” New executive leadership team with deep experience spanning drug development and clinical expertise in AhR bio…
Read attachment ↗ea030567501ex99-1.htm · 8-K · 2026-09-16
EX-99.1 4 ea030567501ex99-1.htm UNAUDITED PRO FORMA CONDENSED BALANCE SHEET OF ADIAL PHARMACEUTICALS, INC. FOR THE QUARTER ENDED JUNE 30, 2026 Exhibit 99.1 ADIAL PHARMACEUTICALS, INC. UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION The following unaudited pro forma condensed financial information presents the historical unaudited consolidated balance sheet as of June 30, 2026 of Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), adjusted to give effect to (i) an amendment to the …
Read attachment ↗ea030359001ex99-1.htm · S-8 · 2026-08-28
Exhibit 99.1 AZORA THERAPEUTICS, INC. 2017 EQUITY INCENTIVE PLAN (As amended, May 25, 2021) 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better aligning the interests of such persons with those of the Company’s stockholders…
Read attachment ↗ea030196601ex99-1.htm · 8-K · 2026-08-17
EX-99.1 2 ea030196601ex99-1.htm PRESS RELEASE, DATED AUGUST 17, 2026 Exhibit 99.1 Adiel Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline Closed initial $32 million tranche, including the conversion of notes, of an up to $64 million private placement from …
Read attachment ↗tm2618725d1_ex99-1.htm · SCHEDULE 13G · 2026-06-24
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersign…
Read attachment ↗ea029444801ex4-1.htm · 8-K · 2026-06-11
EX-4.1 4 ea029444801ex4-1.htm FORM OF PRE-FUNDED WARRANT (FINANCING) Exhibit 4.1 Execution Version THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGIST…
Read attachment ↗